U.S., Jan. 13 -- ClinicalTrials.gov registry received information related to the study (NCT07332143) titled 'Psilocybin-Assisted Randomized Therapy' on Jan. 08.
Brief Summary: This pilot study will examine the safety, tolerability, acceptability, and efficacy of combination psilocybin + psychotherapy to decrease PTSD symptoms. Participants will be randomized into two different treatment groups, allowing the investigators to directly compare PE augmented with psilocybin and psilocybin-assisted psychotherapy.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
PTSD
Intervention:
DRUG: psilocybin
25 mg
BEHAVIORAL: Supportive Therapy
Treatment includes non-directive psychological support across the preparatory, dosing,...